Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrel
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply